| SY007 in Patients With Acute Ischemic Stroke (NCT04891913) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2023-07-01 |
| The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus (NCT05426018) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2022-07-01 |
| SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis (NCT04898322) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2022-01-02 |
| A Food-drug Interaction Study of SY-004 in Healthy Subjects (NCT04907006) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2021-08-31 |
| A Drug Interaction Study of SY-004 Capsules in Healthy Subjects (NCT04907019) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2021-07-06 |
| Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus (NCT04345107) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2020-05-01 |
| The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus (NCT04217291) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2019-12-10 |
| Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects (NCT04217629) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2019-04-26 |
| Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects (NCT04111523) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2019-03-05 |
| Single Ascending Oral Doses of SY-009 in Healthy Subjects (NCT04119947) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2019-03-01 |
| Single Ascending Oral Doses of SY-008 in Healthy Subjects (NCT03462589) | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 2018-08-02 |